Share Email Print

Proceedings Paper

Interstitial laser coagulation of the prostate: experimental studies
Author(s): Thomas A. McNicholas; Adrian C. Steger M.D.; Stephen G. Bown; Neil O'Donoghue
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

A percutaneous, low power, interstitial method of controlled tissue coagulation by laser light has been developed and assessed as a possible alternative to existing therapy for benign and malignant prostatic disease. For prostate cancer this technique may be of importance when the tumor volume is small and well defined, particularly as these tumors can increasingly be identified by transrectal ultrasound (TRUS) and are unlikely to have metastasised. The possibility therefore arises of destruction of such small lesions in situ, thereby avoiding the need for radical surgery or radiotherapy. Using the male beagle prostate model, one or more 150-400 micron fibers was implanted within the substance of the prostate through which a Yttrium Aluminum Garnet (YAG) laser energy could be transmitted. Using long exposures and lower powers than used in routine endoscopic laser therapy, well-defined areas of coagulative necrosis could be created without extensive tissue charring or damage to the fiber. For an energy dose of 1000J a lesion approximately 1 cm in diameter results at four days. The ultrasound scanning methods can detect the fiber(s) and the area(s) of coagulation. At 6/52 months following treatment, healing was by fibrosis or cystic degeneration. There were no ill effects on the subjects following coagulation of the prostate. Multiple fiber experiments produced larger volume lesions relevant to more extensive cancer or for the coagulation of benign adenomatous hyperplasia causing outflow symptoms. Ultrasound guided clinical treatments in patients with cutaneous metastases or hepatic and pancreatic tumors have confirmed the experimental results so far obtained. The technique may prove of value for the destruction of early, small, focal tumors of the prostate and for the treatment of moderate benign enlargement. Clinical trial for both benign and malignant disease has commenced.

Paper Details

Date Published: 1 July 1991
PDF: 6 pages
Proc. SPIE 1421, Lasers in Urology, Laparoscopy, and General Surgery, (1 July 1991); doi: 10.1117/12.43901
Show Author Affiliations
Thomas A. McNicholas, Institute of Urology and National Medical Laser Ctr. (United Kingdom)
Adrian C. Steger M.D., Institute of Urology and National Medical Laser Ctr. (United Kingdom)
Stephen G. Bown, Institute of Urology and National Medical Laser Ctr. (United Kingdom)
Neil O'Donoghue, Institute of Urology and National Medical Laser Ctr. (United Kingdom)

Published in SPIE Proceedings Vol. 1421:
Lasers in Urology, Laparoscopy, and General Surgery
Graham M. Watson M.D.; Rudolf W. Steiner; Joseph J. Pietrafitta M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?